Results 261 to 270 of about 280,575 (305)
Some of the next articles are maybe not open access.
Adjuvant chemotherapy is not for everyone
Breast Cancer Research and Treatment, 2010The history of breast cancer therapy is cyclical [1]. Each new treatment, whether surgery, hormone therapy, or chemotherapy is initially applied to all patients, but with time, usually 10–20 years, it becomes clear that the overall benefit is substantially smaller than first anticipated because only a portion of treated patients derive any benefit ...
openaire +2 more sources
Rationale for adjuvant chemotherapy
Cancer, 1977Surgery or radiation therapy fails to cure clinically evident human cancer, in the main, if the disease is systemic (has metastasized) when first recognized, because neither modality can effectively remove or kill distant and/or unrecognized metastases.
openaire +2 more sources
Adjuvant castration versus adjuvant chemotherapy
International Journal of Radiation Oncology*Biology*Physics, 1978Furthermore, in premenopausal women under 45 years of age Meakin et al.” failed to observe a significant difference in terms of delay of recurrence and prolongation of survival between those who had radical mastectomy (RM) and RM plus ovarian irradiation (RT). Since histologically positive axillary lymph nodes were identified in 87% (RM) and in 98% (RT)
openaire +2 more sources
JAMA, 1984
JUST a little over eight years ago I expressed my concerns 1 about the uncritical and premature acceptance of the results of the then recently published adjuvant study by the National Surgical Breast Project (NSABP). 2 The NSABP report detailed early results of a randomized study of patients who had undergone mastectomy with axillary lymph nodes ...
openaire +3 more sources
JUST a little over eight years ago I expressed my concerns 1 about the uncritical and premature acceptance of the results of the then recently published adjuvant study by the National Surgical Breast Project (NSABP). 2 The NSABP report detailed early results of a randomized study of patients who had undergone mastectomy with axillary lymph nodes ...
openaire +3 more sources
Adjuvant chemotherapy in pancreatic cancer
International journal of pancreatology, 1997There is increasing interest in the use of adjuvant treatment for pancreatic cancer since although postoperative mortality is much improved, median long-term survival is only on the order of 11-15 mo. Despite a proliferation of studies in advanced pancreatic cancer indicating a benefit for chemotherapy, there has only been one small randomized adjuvant
S R, Bramhall, J P, Neoptolemos
openaire +2 more sources
Adjuvant chemotherapy for colon cancer
Best Practice & Research Clinical Gastroenterology, 2002Colorectal cancer is one of the most frequent cancers in the world, especially in occidental countries. The primary curative therapy is surgical resection of the tumour. Within the last 15 years, appropriately powered prospective randomized trials have demonstrated that adjuvant post-operative chemotherapy should be the standard treatment for stage III
M, Ducreux, V, Boige
openaire +2 more sources
Adjuvant chemotherapy of breast cancer
JAMA: The Journal of the American Medical Association, 1980Because of remarkable early success in trials of adjuvant chemotherapy for breast cancer, the National Institutes of Health recently sponsored a consensus conference to evaluate the data in this field and to examine "the impact of such trials on general medical practice." Clear-cut recommendations emerged after two days of presentations and ...
openaire +2 more sources
Adjuvant Chemotherapy in Breast Cancer
1982One single course of i.v. cyclophosphamide (30 mg/kg) was given over a 6-day period to 559 mastectomized patients. During a follow-up period of up to 15 years, 241 recurrence and 234 deaths are registered in this group, and 294 recurrences and 283 deaths in the randomized control group of 577 patients.
R, Nissen-Meyer +2 more
openaire +2 more sources
Adjuvant chemotherapy in gastric cancer
World Journal of Surgery, 1987AbstractThe results of adjuvant chemotherapy trials in gastric cancer are less favorable in European and Anglo‐American countries than in Japan. The majority of findings in Western countries leads to the conclusion that the routine application of adjuvant chemotherapy for gastric cancer cannot be recommended.
openaire +2 more sources